J3393
J3393 – INJECTION, BETIBEGLOGENE AUTOTEMCEL, PER TREATMENT · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 1 NDC crosswalked
📋 J3393 summary
J3393 is a HCPCS Level II J-code used to bill BETIBEGLOGENE AUTOTEMCEL, PER TREATMENT. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J3393: Zynteglo
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ3393
DescriptorINJECTION, BETIBEGLOGENE AUTOTEMCEL, PER TREATMENT
Billing unitNot available in current dataset
Payment limit / unit Not available in current dataset
Mapped NDCs1
Data periodNot available in current dataset
Last updatedSource date not available
💊 About Betibeglogene autotemcel Injection DRUG GUIDE
Zynteglo is approved to treat β-thalassemia — a genetic blood disorder in which the body cannot make enough working hemoglobin — in adult and pediatric patients who require regular red blood cell transfusions to survive.It is a one-time treatment, not an ongoing medication.
The goal is to reduce or eliminate the need for those lifelong transfusions.
Clinical overview from our editorial drug guide for Betibeglogene autotemcel Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS
Medicare payment limit / unit
—
Est. ASP / unit
—
Est. after 2% sequester
—
HCPCS dosage
—
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J3393 = 1 unit. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J3393 CROSSWALKED NDCs
1 NDC map to J3393. Bill units = how many HCPCS units one package represents.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|
| 73554-3111-01 | Zynteglo betibeglogene autotemcel 20000000 1/1 SUSPENSION | Genetix | 1 SUSPENSION in 1 BAG (73554-3111-1) | 20000000 1/1 | 1 | — | ● Active | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
🗺️ Where J3393 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J3393
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Not available
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
No reportable utilization
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J3393 billing FAQ
What is HCPCS code J3393?
J3393 is a HCPCS Level II J-code used to bill INJECTION, BETIBEGLOGENE AUTOTEMCEL, PER TREATMENT under Medicare Part B and most medical (not pharmacy) benefits.
Which NDCs bill under J3393?
1 NDC currently map to J3393 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J3393 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.